Pharmaceuticals

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

A strategic partnership integrates cutting-edge AI into drug development, promising to slash timelines and costs. Is this the new blueprint for pharma R&D?

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.